Consistent therapeutic efficacy was replicated in another primary CCA model established through KRASG12D/P19 CRISPR (KRAS/P19) plasmids transfection (Fig. 2I-P, Supplementary Fig. 5E-H). This evidence concerns the gene KRAS and cholangiocarcinoma.